तुलना करने के लिए मीट्रिक्स | BIAF | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंधBIAFपीअर्सक्षेत्र | |
|---|---|---|---|---|
पी/ई अनुपात | −0.2x | −2.4x | −0.4x | |
PEG अनुपात | 0.00 | −0.04 | 0.00 | |
क़ीमत/बुक | 0.7x | 2.1x | 2.6x | |
क़ीमत / एलटीएम बिक्री | 0.4x | 15.7x | 3.1x | |
अपसाइड (विश्लेषक लक्ष्य) | - | 90.5% | 47.7% | |
उचित मूल्य अपसाइड | अनलॉक करें | 6.3% | 6.5% | अनलॉक करें |
bioAffinity Technologies, Inc. engages in developing non-invasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United States. The company operates through two segments: Diagnostic Research and Development; and Laboratory Services. The company offers CyPath lung which uses flow cytometry technology to detect and analyze cell populations in a person’s sputum, or phlegm, to find characteristics indicative of lung cancer, including cancer and/or cancer-related cells that have shed from a lung tumor. bioAffinity Technologies, Inc. was incorporated in 2014 and is based in San Antonio, Texas.